Education
About Us
Working with TipRanks
Follow Us
Stayble Therapeutics AB (SE:STABL)
:STABL
RESEARCH TOOLSreports
Top Page
Stayble Therapeutics AB
(Frankfurt:STABL)
Rating:34Underperform
Price Target:―
Stayble Therapeutics AB (STABL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
€29.19M
Dividend YieldN/A
Average Volume (3M)815.97K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS Growth63.82%
CountrySE
Employees2
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding64,359,795
10 Day Avg. Volume1,860,390
30 Day Avg. Volume815,965
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.53
Price to Sales (P/S)0.00
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Stayble Therapeutics AB Business Overview & Revenue Model
Company DescriptionStayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
How the Company Makes MoneyStayble Therapeutics AB generates revenue through the development and eventual commercialization of its proprietary treatment solutions for degenerative disc disease. The company primarily invests in clinical trials and research to bring its products to market, aiming to license its technologies to larger pharmaceutical companies upon successful trial results. Significant revenue streams are expected to arise from licensing agreements, milestone payments, and royalties from sales of approved therapies. Partnerships with research institutions and healthcare organizations may also contribute to its earnings by bolstering research capabilities and expanding market reach.
Stayble Therapeutics AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | ― | Gross Profit |
| 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | ― | EBIT |
| -13.06M | -23.95M | -24.80M | -12.14M | -14.93M | -6.87M | EBITDA |
| -8.39M | 309.41K | 0.00 | 0.00 | 0.00 | 0.00 | Net Income Common Stockholders |
| -12.42M | -23.74M | -24.23M | -12.04M | -16.05M | -7.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.19M | 14.08M | 12.85M | 37.47M | 10.87M | 3.82M | Total Assets |
| 9.26M | 21.70M | 19.15M | 43.64M | 18.00M | 9.72M | Total Debt |
| 0.00 | 850.00K | 850.00K | 850.00K | 850.00K | 1.35M | Net Debt |
| -2.19M | -13.23M | -12.00M | -36.62M | -10.02M | -2.47M | Total Liabilities |
| 2.38M | 5.19M | 3.87M | 3.83M | 2.45M | 10.01M | Stockholders Equity |
| 6.87M | 16.51M | 15.28M | 39.81M | 15.55M | -295.44K |
| Cash Flow | Free Cash Flow | ||||
| -14.67M | -23.54M | -24.89M | -9.63M | -23.98M | 289.39K | Operating Cash Flow |
| -14.67M | -23.54M | -24.89M | -9.63M | -23.98M | 289.39K | Investing Cash Flow |
| 0.00 | 0.00 | 1.00K | -1.00K | 0.00 | 0.00 | Financing Cash Flow |
| 2.78M | 24.96M | 1.00 | 36.15M | 31.19M | 500.00K |
Stayble Therapeutics AB Technical Analysis
Negative
0.43
Price Trends
0.47
Negative
0.45
Negative
0.54
Negative
Market Momentum
>-0.01
Positive
42.49
Neutral
23.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.47, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.49 is Neutral, neither overbought nor oversold. The STOCH value of 23.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.
Stayble Therapeutics AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Performance Comparison
SE:STABL
Stayble Therapeutics AB
0.43
0.17
63.36%
DE:9F1
Diagonal Bio AB
―
―
―
DE:5LD
LIDDS AB
0.01
0.00
0.00%
DE:9RP
Lipigon Pharmaceuticals AB
0.02
0.01
100.00%
DE:COJ0
CombiGene AB
0.17
-0.07
-29.17%
DE:99B0
QuiaPEG Pharmaceuticals Holding AB
―
―
―
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.